Please Wait
Applying Filters...
menu
    • menu
    Seqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

    Virtual Booth

    Contact Supplier

    AbbVie Contract Manufacturing partners globally to develop, scale, and manufacture pharmaceutical products successfully.

    Virtual Booth

    Contact Supplier

    Topscience Biotech is a one-stop supplier of sodium hyaluronate//drug manufacturing license, CEP, GMP, DMF, and Form 41 certifications.

    Virtual Booth

    Contact Supplier

    Zach System is committed to providing Highly Customized Solutions for all your Development Programs.

    Virtual Booth

    Contact Supplier

    EUROAPI, the leading small molecules API player, provides both API sales & CDMO services.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    An Enquiry

    Menu

    Aramchol

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls

    Filters

    clear-filterReset all filters
    Left Arrow
    Right Arrow

    Digital Content read-more

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Tissue Dynamics, Galmed Uncover Metabolic Pathway in Fibrosis
    Tissue Dynamics, Galmed Uncover Metabolic Pathway in Fibrosis

    02 Jun 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/tissue-dynamics-and-galmed-unveil-unknown-metabolic-pathway-for-cardiac-fibrosis-and-heart-failure-which-supports-the-development-of-aramchol-for-cardiac-fibrosis-302788311.html

    PR NEWSWIRE
    02 Jun 2026
    Share Share
    Galmed's Oral Aramchol Meglumine Boosts Bioavailability 500%
    Galmed's Oral Aramchol Meglumine Boosts Bioavailability 500%

    14 May 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-results-from-first-in-man-pharmacokinetics-study-of-oral-formulation-of-aramchol-meglumine-am-400mg-am-increases-bioavailability-by-500-in-comparison-to-aramchol-free-acid-aa-300mg-302772195.html

    PR NEWSWIRE
    14 May 2026
    Share Share
    Galmed Reports Significant AM-001 Study Results For Aramchol
    Galmed Reports Significant AM-001 Study Results For Aramchol

    18 Nov 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-meaningful-top-line-results-from-am-001-study-of-aramchol-meglumine-302618567.html

    PR NEWSWIRE
    18 Nov 2025
    Share Share
    galmed identifies biomarker for aramchol, expanding beyond NASH
    galmed identifies biomarker for aramchol, expanding beyond NASH

    27 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-identifies-proprietary-biomarker-signature-for-aramchol-unlocking-multi-billion-dollar-expansion-potential-beyond-nash-302465691.html

    PR NEWSWIRE
    27 May 2025
    Share Share
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models
    Galmed Reports Anti-Fibrotic Effects of Aramchol in PSC Models

    13 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-reports-significant-anti-fibrotic-effects-of-aramchol-in-psc-models-302453710.html

    PR NEWSWIRE
    13 May 2025
    Share Share
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models
    Galmed: Aramchol Boosts Bayer's Regorafenib in GI Cancer Models

    06 May 2025

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/galmed-announces-first-time-results-in-oncology-studies-aramchol-significantly-enhances-bayers-regorafenib-effect-in-gi-cancer-models-302447161.html

    PR NEWSWIRE
    06 May 2025
    Share Share
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.